Drug Trial Radar · NCT05659576
Reducing Acute Upper Gastrointestinal Side-Effects of Thoracic Irradiation
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
142
Actual
Start
Dec 13, 2022
Primary completion
Aug 26, 2026
Study completion Aug 26, 2026
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to explore options for preventing and reducing symptoms of radiation esophagitis (RE). The researchers will also look what symptoms participants experience, and whether there are differences in weight loss in participants.
Conditions
- Radiation Esophagitis
Interventions
SucralfateDrug
1. Sucralfate, 1 gram/10 mL oral suspension "By mouth, take 10 mL twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime".May increase frequency up to 4 times per day, per physician discretion". Or 2. Sucralfate 1 gram tablets By mouth, take one (1) tablet mixed in 15-30 mL warm water twice a day until RT completion, with one dose 30-60 minutes prior to their midday meal and the second dose prior to bedtime". The frequency of sucralfate can be adjusted at anytime at the treating physician's discretion after the patient has started it at twice a day, and the patient may discontinue sucralfate at anytime after RT completion, per physician discretion. May increase frequency up to 4 times per day, per physician discretion".
Usual CareOther
Standard supportive care by using opioids.
One consentOther
Patient will sign one consent form.
Two consentOther
Patient will sign two consent forms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Accrual rate (Two-stage consent part)Time frame: 1 year
- Reduce opioid useTime frame: 2 years
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)
Basking Ridge, New Jersey
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Middletown, New Jersey
Memorial Sloan Kettering Bergen (All Protocol Activities)
Montvale, New Jersey
Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities )
Commack, New York
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York
Memorial Sloan Kettering Nassau (All Protocol Activities)
Uniondale, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.